Non-FDA-approved CAR T-cell therapies with complete clinical trial data available
| . | Allo-715 . | MCARH109 . | Xuzhou GPRC5D CAR T cell therapy . | OriCAR-017 . |
|---|---|---|---|---|
| Trial phase | 1 | 1 | 2 | 1 |
| Target | BCMA | GPRC5D | GPRC5D | GPRC5D |
| Specificity | Allogeneic | Autologous | Autologous | Autologous |
| Patients enrolled (infused) | 48 (43) | 19 (17) | 33 (33) | 13 (10)* |
| Median age (range), y | 64 (46-77) | 60 (38-76)† | 58 (39-70) | 64 (58-68)† |
| Median prior lines (range) | 5 (3-11) | 6 (4-14)† | 4 (2-12) | 5.5 (4-10)† |
| Triple-class refractory, No. (%) | 39 (91) | 16 (94)† | Not reported | Not reported |
| Penta refractory, No. (%) | 18 (42) | Not reported | Not reported | Not reported |
| Prior anti-BCMA CAR T-cell therapy, No. (%) | Excluded | 8 (47)† | 9 (27) | 5 (50)† |
| Received bridging therapy, No. (%) | 0 | 16 (94)† | Not reported | 2 (80)† |
| ORR, No. (%) | 24 (56)† | 12 (71)† | 30 (91) | 10 (100)† |
| CR, No. (%) | Not reported | 6 (35)† | 21 (64) | 6 (60)† |
| ORR in patients with prior anti-BCMA CAR T-cell therapy, No. (%) | 7/10 (70)† | 9/9 (100) | 5 (100)† | |
| Median PFS | Not reported | Not reached | Not reached | Not reached |
| CRS grade 3+, No. (%) | 1 (2) | 1 (6) | 0 (0) | 0 (0) |
| ICANS grade 3+, No. (%) | 0 (0) | 1 (6) | 1 (3) | 0 (0) |
| Trial ID | NCT04093596 | NCT04555551 | ChiCTR2100048888 | NCT05016778 |
| . | Allo-715 . | MCARH109 . | Xuzhou GPRC5D CAR T cell therapy . | OriCAR-017 . |
|---|---|---|---|---|
| Trial phase | 1 | 1 | 2 | 1 |
| Target | BCMA | GPRC5D | GPRC5D | GPRC5D |
| Specificity | Allogeneic | Autologous | Autologous | Autologous |
| Patients enrolled (infused) | 48 (43) | 19 (17) | 33 (33) | 13 (10)* |
| Median age (range), y | 64 (46-77) | 60 (38-76)† | 58 (39-70) | 64 (58-68)† |
| Median prior lines (range) | 5 (3-11) | 6 (4-14)† | 4 (2-12) | 5.5 (4-10)† |
| Triple-class refractory, No. (%) | 39 (91) | 16 (94)† | Not reported | Not reported |
| Penta refractory, No. (%) | 18 (42) | Not reported | Not reported | Not reported |
| Prior anti-BCMA CAR T-cell therapy, No. (%) | Excluded | 8 (47)† | 9 (27) | 5 (50)† |
| Received bridging therapy, No. (%) | 0 | 16 (94)† | Not reported | 2 (80)† |
| ORR, No. (%) | 24 (56)† | 12 (71)† | 30 (91) | 10 (100)† |
| CR, No. (%) | Not reported | 6 (35)† | 21 (64) | 6 (60)† |
| ORR in patients with prior anti-BCMA CAR T-cell therapy, No. (%) | 7/10 (70)† | 9/9 (100) | 5 (100)† | |
| Median PFS | Not reported | Not reached | Not reached | Not reached |
| CRS grade 3+, No. (%) | 1 (2) | 1 (6) | 0 (0) | 0 (0) |
| ICANS grade 3+, No. (%) | 0 (0) | 1 (6) | 1 (3) | 0 (0) |
| Trial ID | NCT04093596 | NCT04555551 | ChiCTR2100048888 | NCT05016778 |